Showing 1 - 10 of 661
In Medicare Part D, low income individuals receive subsidies to enroll into insurance plans. This paper studies how premiums are distorted by the combined effects of this subsidy and the default assignment of low income enrollees into plans. Removing this distortion could reduce the cost of the...
Persistent link: https://www.econbiz.de/10013104108
Cancer often results in catastrophic health expenditures and creates a huge financial burden for families. We study the impact on patient finances and health outcomes of the national centralized drug procurement program in China for leukemia patients. The program reduced the price of the generic...
Persistent link: https://www.econbiz.de/10014256321
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
In early 2004, the U.S. Government initiated the Medicare Discount Drug Card Program, under which a large amount of pharmacy-level price data pertaining to over 800 drugs has been released weekly on the Medicare Web site continuously between May 29, 2004 and October 2005. This extensive...
Persistent link: https://www.econbiz.de/10012734948
Very few industries are as profoundly influenced by regulation as the pharmaceutical industry. All aspects of the life-cycle of new drugs are regulated, from patent application, to marketing approval, commercial exploitation, patent expiration and competition with generics. The nature of demand...
Persistent link: https://www.econbiz.de/10012980141
The United States spends twice as much per person on pharmaceuticals as European countries, in large part because prices are much higher in the US. This fact has led policymakers to consider legislation for price controls. This paper assesses the effects of a US international reference pricing...
Persistent link: https://www.econbiz.de/10013210081
Even in wealthy economies, access to medicines is increasingly affected by medicine shortages – an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the...
Persistent link: https://www.econbiz.de/10013174584
In early 2004, the U.S. Government initiated the Medicare Discount Drug Card Program, which created a market for drug cards that allowed their subscribers to obtain discounts on their prescription drug purchases. Pharmacy-level prices for several drugs were posted on the program website weekly...
Persistent link: https://www.econbiz.de/10012714541
I evaluate how the probability of substitution of a prescribed drug in a pharmacy depends on the pharmacists' profits and patients' out of pocket costs. I use Finnish population-wide data covering all prescriptions of three popular antidepressants. I find that one euro increase in the total...
Persistent link: https://www.econbiz.de/10011954334
Health insurances curb price insensitive behavior and moral hazard of insureds through different types of cost-sharing, such as tiered co-payments or reference pricing. This paper evaluates the effect of newly introduced price limits below which drugs are exempt from co-payments on the pricing...
Persistent link: https://www.econbiz.de/10012982257